Firtecan pegol

Tier C — Watch / trade

Firtecan pegol

Enzon Pharmaceuticals Inc

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：HIF1A, TOP1

Indications (approved)：Colorectal cancer, Breast cancer, Solid tumour, Metastatic breast cancer, Lymphoma

Regional status

Discontinued

2009-06-01

No progress

2009-06-01

China

Phase I

2017-02-08

Japan

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield 0.86 g (Firtecan pegol)

FIRT-00186639-52-3FIRT-002946062-01-7FIRT-0034530-20-5FIRT-004946062-02-8FIRT-005946062-03-9FIRT-0095292-43-3FIRT-006—FIRT-007—FIRT-008—FIRT-010—API · Firtecan pegol

Code	CAS No.	Intermediate
FIRT-001	86639-52-3 Available	(S)-4,11-diethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione
FIRT-002	946062-01-7	(S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione
FIRT-003	4530-20-5 Available	2-((tert-butoxycarbonyl)amino)acetic acid
FIRT-004	946062-02-8	(S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl (tert-butoxycarbonyl)glycinate
FIRT-005	946062-03-9	(S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl glycinate hydrochloride
FIRT-009	5292-43-3	tert-butyl 2-bromoacetate
FIRT-006	-	7,7'-(oxybis(methylene))bis(3,6,9,12-tetraoxatetradecanedioic acid)
FIRT-007	-	tetrakis((S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl) 10,10'-(oxybis(methylene))bis(4,17-dioxo-6,9,12,15-tetraoxa-3,18-diazaicosanedioate)
FIRT-008	-	2,2',2'',2'''-((oxybis(propane-3,1,2-triyl))tetrakis(oxy))tetrakis(ethan-1-ol)
FIRT-010	-	tetra-tert-butyl 7,7'-(oxybis(methylene))bis(3,6,9,12-tetraoxatetradecanedioate)

Frequently asked questions

What are the approved indications of Firtecan pegol?

Approved indications include: Colorectal cancer, Breast cancer, Solid tumour, Metastatic breast cancer, Lymphoma.

When does the Firtecan pegol patent expire?

No public expiry year is available for Firtecan pegol yet; this page updates once verified.

How many synthesis routes are recorded for Firtecan pegol?

1 synthesis routes are recorded; the shortest is 7 steps with 0.86 g (Firtecan pegol) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Firtecan pegol intermediates?

2 intermediate CAS of Firtecan pegol are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Firtecan pegol intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21